Immunoglobulin G4 (IgG4) Related Disease - Wesley Research Institute
Wesley Research Institute

Testing new treatments for people with IgG4 related disease (fibro-inflammatory condition).

Research Objectives



Estimated completion

December 2025

Total participants required


Study location

The Wesley Hospital

About this clinical trial

There are currently no medicinal products approved for the treatment of IgG4-RD. The majority of cases follow a relapsing course that can lead to permanent tissue damage with potential morbidity and mortality. This project aims to develop an effective product.

The purpose of this study is to better understand the safety and side effects of  Inebilizumab and to find out if it helps people with IgG4 related disease.


Do you meet the following criteria?

Adults aged ≥ 18 years who have recently active IgG4-RD (initial diagnosis or flare) that requires new or ongoing treatment, are at high risk of future flare, and meet the 2019 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR)IgG4-RD classification criteria.

Additional information

You can find out more about the MITIGATE trial by visiting the website.

Lead investigators

  • Dr Daman Langguth

Technical title

A Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in Immunoglobulin G4-related disease (IgG4) Related Disease (MITIGATE)

Register your interest

If you would like more information about this clinical trial, please complete the contact form below.

DD slash MM slash YYYY
Which if the following accurately describes you?(Required)

Would you like to be updated on the progress of our research?(Required)
By submitting this form you consent for us to hold your information in accordance with our Privacy Policy
This field is for validation purposes and should be left unchanged.
linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram